Praxis Precision Medicines, Inc. (PRAX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Praxis Precision Medicines, Inc. (PRAX) Healthcare & Pipeline Overview

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) disorders, leveraging targeted therapies to address neuronal imbalances. With a diverse pipeline including Phase II trials, Praxis aims to deliver innovative treatments for conditions like depression, essential tremor, and epilepsy, positioning them within the competitive biotechnology landscape.

What Is the Investment Thesis for PRAX?

Praxis Precision Medicines, Inc. presents a notable research candidate due to its focused approach on CNS disorders and a diversified pipeline of clinical-stage assets. Key value drivers include the advancement of PRAX-114 and PRAX-944 through Phase II trials, with potential readouts expected in the next 12-18 months. The company's collaborations with Ionis Pharmaceuticals and The Florey Institute further de-risk its pipeline and provide access to cutting-edge technologies. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $9.44B and a beta of 2.97, Praxis exhibits significant growth potential but also heightened volatility. Successful clinical outcomes and strategic partnerships will be critical for driving long-term value.

Based on FMP financials and quantitative analysis

PRAX Key Highlights

PRAX-114 is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.

• PRAX-944 is in Phase IIa clinical trial for the treatment of essential tremor.
• PRAX-562 is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia.
• The company has a market capitalization of $9.44B.
• Praxis has a cooperation and license agreement with RogCon Inc. and a research collaboration with Ionis Pharmaceuticals, Inc.

Who Are PRAX's Competitors?

PRAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRAX's Key Strengths?

Diverse pipeline of clinical-stage assets.

• Targeted approach to neuronal imbalance in CNS disorders.
• Strategic collaborations with leading research institutions.
• Proprietary drug candidates with patent protection.

What Are PRAX's Weaknesses?

High reliance on clinical trial outcomes.

• Limited commercialization experience.
• Potential for competition from larger pharmaceutical companies.
• High cash burn rate associated with drug development.

What Could Drive PRAX Stock Higher?

Phase IIa clinical trial results for PRAX-114 in major depressive disorder (MDD).

• Phase IIa clinical trial results for PRAX-944 in essential tremor.
• Advancement of PRAX-562 through Phase I clinical trials for severe pediatric epilepsy and adult cephalgia.
• Development of PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy.
• Progress in KCNT1 program for the treatment of KCNT1 GOF epilepsy.

What Are the Key Risks for PRAX?

Negative return on equity (-43.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $2.3M recently.
• Clinical trial failures for key drug candidates.
• Regulatory delays or non-approval of therapies.
• Competition from established pharmaceutical companies and therapies.
• High cash burn rate associated with drug development.
• Dependence on strategic collaborations for research and development.

What Are the Growth Opportunities for PRAX?

• Advancement of PRAX-114 in Depression Treatment: PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator, is currently in Phase IIa clinical trials for major depressive disorder (MDD) and perimenopausal depression. Positive trial results could lead to significant market penetration, offering a novel treatment option for patients who do not respond adequately to existing therapies. The timeline for potential commercialization depends on successful trial outcomes and regulatory approvals.
• Development of PRAX-944 for Essential Tremor: PRAX-944, a selective small molecule inhibitor of T-type calcium channels, is in Phase IIa clinical trials for the treatment of essential tremor. The essential tremor market represents a significant opportunity, with millions affected worldwide. Successful development and commercialization of PRAX-944 could establish Praxis as a leader in this therapeutic area. The timeline for potential market entry hinges on clinical trial success and regulatory pathways.
• Expansion of PRAX-562 for Epilepsy and Cephalgia: PRAX-562, a persistent sodium current blocker, is in Phase I clinical trials for severe pediatric epilepsy and adult cephalgia. Epilepsy and cephalgia represent significant unmet medical needs, particularly in pediatric populations. Positive results from Phase I trials could pave the way for further development and potential market entry. The timeline for commercialization depends on clinical trial progress and regulatory approvals.
• Leveraging Antisense Oligonucleotide (ASO) Technology: Praxis is developing PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy, and a KCNT1 program for the treatment of KCNT1 GOF epilepsy. ASO therapies represent a cutting-edge approach to treating genetic disorders. Successful development of these programs could establish Praxis as a leader in gene-targeted therapies for epilepsy. The timeline for potential market entry is contingent on clinical trial outcomes and regulatory pathways.
• Strategic Collaborations and Licensing Agreements: Praxis has established collaborations with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, Inc., and The Florey Institute. These collaborations provide access to novel technologies and expertise, enhancing Praxis's research and development capabilities. By leveraging these partnerships, Praxis can accelerate the development of its pipeline and expand its therapeutic reach. The impact of these collaborations will be realized through the advancement of partnered programs and the potential for future licensing agreements.

What Opportunities Does PRAX Have?

• Expansion of pipeline through internal research and development.
• Out-licensing or partnering with larger pharmaceutical companies.
• Acquisition of complementary technologies or assets.
• Addressing unmet medical needs in CNS disorders.

What Are PRAX's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in CNS drug development.
• Clinical trial data demonstrating efficacy and safety.
• Strategic collaborations with leading research institutions.

What Does PRAX Do?

Praxis Precision Medicines, Inc., founded in 2015 and based in Boston, Massachusetts, is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. The company's mission is to address diseases characterized by neuronal imbalance through targeted and innovative treatments. Praxis's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently in Phase IIa clinical trials for major depressive disorder and perimenopausal depression. Another key candidate is PRAX-944, a selective small molecule inhibitor of T-type calcium channels, also in Phase IIa clinical trials for essential tremor. Beyond these, Praxis is developing PRAX-562, a persistent sodium current blocker in Phase I clinical trials for severe pediatric epilepsy and adult cephalgia. The company also has PRAX-222, an antisense oligonucleotide (ASO) targeting gain-of-function (GOF) SCN2A epilepsy, and a KCNT1 program for KCNT1 GOF epilepsy. These programs reflect Praxis's commitment to addressing a range of neurological conditions with significant unmet medical needs. Praxis has established strategic collaborations to enhance its research and development efforts, including agreements with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, Inc., and The Florey Institute. These collaborations provide access to novel technologies and expertise, supporting the development of innovative therapies for CNS disorders.

What Products and Services Does PRAX Offer?

• Develop therapies for central nervous system (CNS) disorders.
• Focus on diseases characterized by neuronal imbalance.
• Develop PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator for depression.
• Develop PRAX-944, a selective small molecule inhibitor of T-type calcium channels for essential tremor.
• Develop PRAX-562, a persistent sodium current blocker for severe pediatric epilepsy and adult cephalgia.
• Develop PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy.
• Develop KCNT1 program for the treatment of KCNT1 GOF epilepsy.

How Does PRAX Make Money?

• Develops and patents novel therapeutic compounds.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• May out-license or partner with larger pharmaceutical companies for commercialization.

What Industry Does PRAX Operate In?

Praxis Precision Medicines operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The CNS therapeutics market is driven by an increasing prevalence of neurological disorders and a growing demand for innovative treatments. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Praxis differentiates itself through its targeted approach to neuronal imbalance and its focus on specific genetic targets. The biotechnology industry is expected to continue growing, driven by technological advancements and an aging global population.

Who Are PRAX's Key Customers?

• Patients suffering from central nervous system disorders.
• Physicians who prescribe medications for these conditions.
• Hospitals and clinics that treat patients with CNS disorders.
• Pharmaceutical companies that may license or acquire Praxis's therapies.

Praxis Precision Medicines, Inc. Financial Trajectory

Praxis Precision Medicines, Inc. (PRAX) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $83.7M, with diluted EPS of $-2.87. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, PRAX averaged $-3.35 in diluted EPS.

Company Profile

Praxis Precision Medicines, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Marcio Silva De'Souza. PRAX has traded publicly since 2020.

How Praxis Precision Medicines, Inc. Is Valued

Praxis Precision Medicines, Inc. carries a market capitalization of $9.44B, placing it in the mid-cap category. Analyst price targets span from $162.00 to $1201.00, with a consensus of $603.83. At the current price of $338.57, that implies approximately 78% upside potential. Relative to its peer group, PRAX's quantitative score of 60/100 is below the peer average of 75/100.

Return on equity for Praxis Precision Medicines, Inc. stands at -43.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -22.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.7%, the inverse of the P/E and a quick read on earnings relative to price.

Praxis Precision Medicines, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Praxis Precision Medicines, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.6% below estimates on average.

Over the past six months, Praxis Precision Medicines, Inc. insiders filed 39 SEC Form 4 transactions — 16 sales and 23 purchases. On net that is roughly 18K shares disposed (about $2.3M), a signal worth weighing alongside the fundamentals.

PRAX Financials

PRAX Latest News

PRAX Analyst Consensus

PRAX MoonshotScore

What Investors Ask About Praxis Precision Medicines, Inc. (PRAX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources